secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001437749-26-011831
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences appoints Liane Teplitsky COO; expands Dr. Kenigsberg as full-time CMO
--------------------------------------------------------------------------------

- Liane Teplitsky named COO effective April 8, 2026; oversees Clinical, Regulatory, Quality, Commercial functions.
- Received inducement award: 700,000 stock options ($19.06) and 200,000 RSUs; vesting tied to market cap and revenue milestones.
- Dr. David Kenigsberg expands to full-time Chief Medical Officer, continues active practice; will lead IDE pivotal study for nPulse catheter.
- Two other new employees granted inducement options for 7,700 shares total at $19.06, time-vesting over four years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926011831/0001437749-26-011831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926011831/plse20260316_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-011831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer